Mosaic nanoparticle vaccine approach could help combat future coronavirus pandemics

A new experimental vaccine developed by researchers from the Massachusetts Institute of Technology, Massachusetts General Hospital, Caltech, and the University of Cambridge in the United Kingdom could offer protection against emerging variants of SARS-CoV-2, as well as related coronaviruses, known as sarbecoviruses, that could spill over from animals to humans. Sarbecoviruses include SARS-CoV-2 (the virus that causes COVID-19) and the virus that led to the outbreak of the original SARS in the early 2000s. By attaching up to eight different versions of sarbecovirus receptor-binding proteins to nanoparticles, the researchers created a vaccine that generates antibodies that recognize regions of receptor-binding proteins that tend to remain unchanged across all strains of the viruses.